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Cheshire, Warrington and Wiral (12,091mg) –18.2 fold difference. Imatinib, highest: 
East Anglia (370,461mg); lowest: Leicestershire and Lincolnshire (71,592mg) –5.2 
fold difference. Denosumab, highest: Cheshire, Warrington and Wiral (11,281DDD); 
lowest: Merseyside (0DDD). ConClusions: There are large variations in local pre-
scribing between different NICE-approved oncology drugs, which exceeds what 
might have been expected from variations in local demographics. The ongoing frag-
mentation of the NHS particularly with respect to specialised service provision will 
likely further exacerbate this geographical variability in coverage and potentially 
fuel a greater ‘postcode lottery.’
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objeCtives: To review evidence-based processes used in UK cancer fund-
ing decisions, using biologics in metastatic colorectal cancer (mCRC) as a case 
study. Methods: We conducted an analysis of the peer-reviewed literature report-
ing overall survival (OS) in mCRC in randomised clinical trials (RCTs) and in real 
world studies (RWSs). Additionally, we investigated the use of RCTs and RWSs in UK 
cancer drug funding decisions. Results: Recent RWSs report median OS levels in 
mCRC that are several months longer than those seen in pre-biologic RCTs (approxi-
mately 29.2 months in the post-biologic era versus 17.4 months pre-biologics, an 
incremental survival benefit of 11.8 months). The most recent data show real world 
median OS as long as 32 months. However, the scoring system for cancer funding 
decisions in the UK is currently predominantly focused on pre-launch RCT data, 
with no data drawn from RWSs referenced in National Institute for Health and Care 
Excellence (NICE) and Clinical Reference Group (CRG) evaluations. ConClusions: 
The current focus of the cancer funding scoring system on pre-launch RCTs may 
miss value gained from ‘innovation-in-use.’ Additionally, treatment holidays and 
sequencing steps could lead to further cost reductions that might increase value 
even without impact on OS. Therefore, NICE evaluations and the methodology for 
CRG scoring may undervalue the reality of real-world experience. The Cancer Drugs 
Fund (CDF) enables the UK National Health Service to realize the full scope of ben-
efits of innovative drugs, overcoming the deficiencies currently inherent in NICE and 
CRG processes. Therefore, considerations for delisting of drugs from the CDF should 
be made in the light of data from RWSs as well as pre-launch data.
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objeCtives: Spending on oncology medications accounts for a growing share of 
total medical spending, raising questions about the financial sustainability of 
pricing regimes and continued progress against cancer. This research evaluates oncol-
ogy spending across product classes, shedding light on the impact of loss of exclu-
sivity (LOE) and new product entry in order to provide focus and an improved fact 
basis for discussions of financial sustainability in oncology treatment. Methods: 
Quarterly observations on national-level sales of oncology medication in each of the 
five largest European markets, the US and Japan are compiled from IMS Health data 
from 2001 to 2013. These data are evaluated by medication type (cytotoxics, hormonals 
and targeted therapies) and brand/generic/biologic status, to evaluate the impact of 
LOE and new product entry with an eye toward projecting future oncology spending. 
Spending levels on oncology products by therapy type, country and exclusivity status 
are juxtaposed with patterns of hyperlipidemia and anti-ulcer products to assess the 
differences in sales patterns as product classes mature and lose exclusivity. Results: 
Although there is considerable variation across countries, it is generally observed that 
small-molecule oncologic products experience a classic “patent cliff” around LOE. For 
example, total spending on cytotoxics (chemotherapy agents) in the US peaked in 
late 2011 and declined to 83% of peak levels by late 2013; generics comprised 12% of 
total spending in 2001, and 28% of total spending by late 2013. Targeted therapies, on 
the other hand, have experienced consistent sales growth, with much of that growth 
occurring for biologic therapies. ConClusions: Oncology spending in major global 
markets does not appear to be fundamentally unsustainable. Questions about future 
spending growth are appropriately focused on targeted therapies, particularly on 
biologic products, suggesting that the emergence of biosimilars will play a central 
role in shaping oncology spending in coming years.
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objeCtives: To characterise UK Cancer Drug Fund (CDF) scoring of breast can-
cer drugs using the CDF prioritisation tool and to assess the final decisions made 
by the Chemotherapy Clinical Reference Group (CCRG) and the national CDF 
panel. Methods: The CDF decision summaries (available online at www.england.
nhs.uk/ourwork/pe/cdf/cdf-drug-sum) record the formal decisions of the CCRG in 
relation to drugs and drug indications that are reviewed for inclusion on the national 
CDF list. We reviewed the individual scoring for each treatment in the criteria using 
the CDF prioritisation tool. Assessed criteria included: magnitude of survival benefit 
(progression free survival and overall survival), quality of life, toxicity compared 
with existing therapies, degree of unmet clinical need, strength of evidence and 
total score. Results: Between April 2013 and May 2015, 15 decision summaries 
assessing 7 drugs for the treatment of breast cancer were reported by the CCRG. Of 
these summaries, 5 saw a positive overall decision and 10 were negative. The over-
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objeCtives: MCDA allows structured consideration of the many aspects of value 
appraisal in healthcare. This study explored the value of lenvatinib for RR-DTC using 
holistic MCDA (EVIDEM framework). Methods: The framework integrated 12 quan-
titative and 7 qualitative contextual criteria, each derived from fundamental ethical 
positions. By-criterion lenvatinib evidence matrices were designed for three countries 
(France, Italy, Spain) and two comparators (watch and wait, sorafenib) based on a 
systematic review and proprietary data. Value appraisal was performed by collecting 
weights (individual perspectives), scores (performance of lenvatinib) and qualitative 
inputs (impact of context) from three structured panel sessions designed to include 
patients, physicians, health economists and policy-decisionmakers, convened under 
the Chatham house rule. Value contributions (WeightsXScores) for each criterion and 
variability across individuals, countries and weighting methods were analyzed. Data 
on usefulness of the process were collected. Results: The greatest weights were 
given to criteria Comparative effectiveness together with Quality of evidence (Spain 
and Italy) or Disease severity (France). Across all countries and comparators, four cri-
teria contributed most to the value of lenvatinib (Comparative effectiveness [16-22%], 
Disease severity [16-22%], Unmet needs [14-21%], Quality of evidence [14-20%]), with 
contributions varying by comparator and country. Some negative contributions were 
observed for criteria Comparative safety (versus watch and wait) and Comparative 
economic consequences. The overall value of lenvatinib was positive across countries 
and comparators with variability across individuals, countries and weighting meth-
ods. Impacts of contextual criteria varied noticeably across countries, highlighting 
the importance of local consultation. Panelists reported the process contributed to 
their understanding of the intervention and its context and was helpful to express 
and share their perspectives and knowledge. ConClusions: Using MCDA-based 
holistic appraisal, the value of lenvatinib was assessed as consistently positive in the 
diverse treatment landscapes. The method provides a structured means to collect 
country-specific data and facilitates exchange across stakeholders.
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objeCtives: Cost-per-QALY (CPQ) threshold can be a useful tool for resource alloca-
tion decisions but also may constitute an obstacle in access to the most-innovative, 
often life-saving but also expensive medicines. Since cancer is a major challenge 
for all healthcare systems, we investigated the impact of CPQ policy on new cancer 
drug reimbursement in 6 Central and Eastern Europe (CEE) countries: Poland and 
Slovakia (CPQ-driven countries), Czech Republic and Hungary (CPQ-oriented coun-
tries), Croatia and Romania (non-CPQ countries). Methods: Basing on predefined 
criteria we selected 13 drug-indication pairs and considered their reimbursement 
status, time from registration to positive reimbursement decision and possible 
factors influencing reimbursement decision. Analyzes were performed for each 
selected country separately and in pairs grouped with regard to CPQ policy. The 
results were compared with indicators illustrating reimbursement systems, general 
cancer care and economics of participating countries. Results: Generally, in all 
participating countries, cancer drugs generating lower CPQ values were more likely 
to be reimbursed. Analysis based on multinomial model adjusting for factors that 
might impact reimbursement decision confirmed significant role of CPQ value of 
a drug and GDP per capita of a country. Medicines generating higher CPQ values or 
evaluated in countries with lower GDP per capita are less likely to obtain positive 
reimbursement decisions. ConClusions: CEE countries have a different approach 
to CpQ application in reimbursement decisions. Access to oncology treatment for 
patients in CEE seems to be affected and not necessary improved by CPQ imple-
mentation policy. Higher CPQ value results in more constrained access to cancer 
drugs and prolonged time to reimbursement decision. CPQ is not the only criterion 
in the reimbursement process and even when met does not inevitably transfer into 
positive reimbursement decision. It seems that currently factors related to economy 
of CEE countries may affect reimbursement by far more than strictly CPQ policy.
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objeCtives: Access to drugs, particularly high cost oncology medicines, across 
England has frequently been accused to operate under a ‘postcode lottery’ where 
access varied depending on where you live. Since 2012, the National Institute of 
Health and Care Excellence (NICE) recommendations are mandated to be followed 
nationally within 90 days of issuing. Nevertheless, further regional/local restrictions 
upon usage are not uncommon that, along with the duration of NICE decision-
making and non-universal coverage of medicines by NICE, leads to variability in 
prescribing levels of high cost medicines. Furthermore, NHS commissioning of 
specialised services is moving towards increasing co-commissioning between the 
local Clinical Commissioning Group (CCG) teams and regional/local NHS England 
bodies (formally Area Teams), with diverse models of care and service specifica-
tions being set out as part of the NHS 5 Year Forward View. This research aims to 
evaluate the level of regional variation in NHS prescribing. Methods: All cancer 
drug prescribing data from the most recent NHS innovation scorecard heat map 
(July-September 2014) was extracted. Variations in prescribing across the 25 Area 
Teams per 100,000 population were identified. Results: Data for three oncology 
drugs was available: denosumab, imatinib and nilotinib; NICE has issued positive 
guidance for all of these. Stark variations in amount prescribed between differ-
ent area teams were apparent. Nilotinib, highest: Merseyside (220,385mg); lowest: 
